Q32 Bio presents 36-week SIGNAL-AA Part B results; 35.3% mean SALT reduction, durable off-drug responses

Q32 Bio reported clinically meaningful Week 36 efficacy for bempikibart with a 35.3% mean SALT reduction and durable responses through 16 weeks off-drug.Key Highlights:Original SEC Filing: Q32 Bio Inc. [ QTTB ] - 8-K - Sep. 30, 2026This is an AI-powered summary. It may contain inaccuracies. Conside…